|Bid||10.70 x 1200|
|Ask||11.56 x 1400|
|Day's Range||10.89 - 11.60|
|52 Week Range||10.35 - 23.85|
|Beta (3Y Monthly)||-0.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.33|
HENDERSON, NV / ACCESSWIRE / October 18, 2018 / Below are a few Medical stocks that are in position to make their investors major profit in the coming sessions.The company on our radar today, however, ...
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Dynavax Technologies Corporation (DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the immunotherapy combination of Dynavax’s proprietary investigational compound SD-101 and KEYTRUDA® (pembrolizumab) will be evaluated in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer. SD-101 is expected to augment responses to anti-PD-1 therapy as has been reflected in early clinical studies of other tumor types.
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, ...
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).
BERKELEY, Calif., Oct. 09, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating.
Nobel Prize winner Jim Allison is in Texas, but the Nobel Prize win Monday for his cancer immunotherapy work reverberates in the Bay Area.
BERKELEY, Calif., Sept. 27, 2018-- Dynavax Technologies Corporation today announced that Eddie Gray, Dynavax’ s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on ...
Dynavax Technologies Corporation (DVAX) today announced publication of a preclinical study demonstrating that inhalation of a TLR9 agonist can stimulate effective immunity against lung tumors and complement the actions of PD-1 blockade to generate durable, systemic anti-tumor immunity. The paper titled Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay, by Dynavax scientists M.Gallotta, H. Assi, E. Degagné, S. Kannan, R.Coffman and C. Guiducci was published in the journal Cancer Research.
Dynavax Technologies Corporation (DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been published by Cancer Discovery, a journal publication from American Association of Cancer Research (AACR). The investigators report clinical activity and broad immune activation in the tumor microenvironment when SD-101 is administered in combination with either low dose radiation in patients with indolent lymphoma or in combination with PD-1 blockade in patients with unresectable or metastatic melanoma. “Promising data from multiple trials studying intratumoral administration of TLR9 agonists indicate that stimulating the innate immune system through the TLR9 pathway can enhance the adaptive immune response to both injected and non-injected tumors,” said Antoni Ribas, M.D., Ph.D., Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center.
Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National ...
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -6.78% and -24.23%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Berkeley, California-based company said it had a loss of 63 cents. The biopharmaceutical company posted revenue of $1.3 million in the period. Dynavax Technologies shares have ...
HEPLISAV-B ® Launch Progressing as Planned with Key Customer Successes. Three abstracts accepted for presentation at European Society for Medical Oncology 2018 Annual Meeting. Conference Call to be held ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Dynavax Technologies Corporation (NASDAQ: DVAX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM ...
Dynavax Technologies Corporation (DVAX) today announced that it will report financial results for the second quarter ended June 30, 2018 after market close on Monday, August 6, 2018, and host a conference call that day to review the results and provide an update on the launch of HEPLISAV-B® [Hepatitis B Vaccine, (Recombinant) Adjuvanted] and its oncology program at 4:30pm ET/1:30pm PT. To access the call, participants must dial (800) 239-9838 in the U.S. or (323) 794-2551 internationally, and use the conference ID 2303066. The conference ID for the replay will be 2303066.
Jim Cramer recommended on CNBC's "Mad Money Lightning Round" a long position in Childrens Place Inc (NASDAQ: PLCE ). He would buy the weakness in the stock. Dynavax Technologies Corporation (NASDAQ: ...
Jim Cramer rattles off his take on callers' favorite stocks, including his take on how investors should approach the gold market.
On Friday, July 6, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: CytomX Therapeutics Inc. (NASDAQ: CTMX), Dynavax Technologies Corp. (NASDAQ: DVAX), Edge Therapeutics Inc. (NASDAQ: EDGE), Editas Medicine Inc. (NASDAQ: EDIT).